Cargando…
Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing
BACKGROUND: Tumor mutational burden (TMB) is emerging as a promising biomarker in immune checkpoint inhibitor (ICI) therapy. Despite whole-exome sequencing (WES) being the gold standard for quantifying TMB, TMB is determined by selected targeted panels in most cases, and WES-derived TMB data are lac...
Autores principales: | Zhou, Chuang, Chen, Song, Xu, Fei, Wei, Jinwang, Zhou, Xiaoyu, Wu, Zhiqiang, Zhao, Longshuan, Liu, Jun, Guo, Wenbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506705/ https://www.ncbi.nlm.nih.gov/pubmed/34733989 http://dx.doi.org/10.21037/atm-21-4227 |
Ejemplares similares
-
Influence of low tumor content on tumor mutational burden estimation by whole‐exome sequencing and targeted panel sequencing
por: Zhang, Wenxin, et al.
Publicado: (2021) -
Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories
por: Qiu, Ping, et al.
Publicado: (2016) -
Evaluation of Exome Sequencing to Estimate Tumor Burden in Plasma
por: Klevebring, Daniel, et al.
Publicado: (2014) -
Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing
por: Heydt, Carina, et al.
Publicado: (2020) -
Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing
por: Su, Shan, et al.
Publicado: (2019)